title: Urethral pressure profile and hemodynamic effects of phenoxybenzamine and prazosin in non-sedated male beagle dogs.
abstract: Prazosin is a readily available alpha-adrenergic antagonist that may be useful in the management of functional urethral obstruction in companion animals. This study used urethral pressure profilometry to evaluate the urethral effects of prazosin and phenoxybenzamine in healthy, non-sedated, male Beagle dogs. Heart rate, indirect systolic, diastolic and mean arterial blood pressures were measured, and saline perfusion urethral pressure profilometry was performed at 0, 10, 20, and 40 min following intravenous administration of prazosin (0.025 mg/kg), phenoxybenzamine (0.2 mg/kg), or placebo. Maximal urethral pressure, maximal urethral closure pressure, post peak nadir, and all blood pressure parameters decreased significantly at nearly all treatment intervals following administration of prazosin compared with placebo. Less consistently significant reductions were observed following phenoxybenzamine administration. Maximal decreases in urethral pressure parameters were observed 20 min following the injection of prazosin; maximal blood pressure decreases were evident by 10 min postinjection. In this non-sedated dog model, urethral pressure profilometry was a sensitive method of detecting urethral effects of alpha antagonists. Repeatable reductions in urethral pressure measurements were observed, with prazosin effecting more consistently significant changes than phenoxybenzamine. Significant decreases in systolic, diastolic, and mean arterial blood pressures were seen with prazosin, but not phenoxybenzamine or placebo. Further study of selective alpha-1 antagonists in dogs is needed to determine appropriate oral dosing protocols that will produce maximal urethral effects with minimal hemodynamic effects, and to demonstrate clinical efficacy in dogs with functional urethral obstruction.
authors.affiliation: Department of Companion Animals, Atlantic Veterinary College, University of Prince Edward Island, 550 University Ave, Charlottetown, Prince Edward Island C1A 4P3. jrofischer@ucdavis.edu
authors.forename: Julie R
authors.initials: JR
authors.lastname: Fischer
authors.forename: India F
authors.initials: IF
authors.lastname: Lane
authors.forename: Alastair E
authors.initials: AE
authors.lastname: Cribb
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D006339:Heart Rate / Q000187:drug effects; D007275:Injections, Intravenous / Q000662:veterinary; D007700:Kinetics; D008297:Male; D010643:Phenoxybenzamine / Q000494:pharmacology* / Q000627:therapeutic use; D011224:Prazosin / Q000494:pharmacology* / Q000627:therapeutic use; D011312:Pressure; D011897:Random Allocation; D016896:Treatment Outcome; D014521:Urethra / Q000187:drug effects / Q000502:physiology*; D014524:Urethral Obstruction / Q000188:drug therapy / Q000662:veterinary*; D014563:Urodynamics / Q000187:drug effects / Q000502:physiology
chemical_list: D000317:Adrenergic alpha-Antagonists; D010643:Phenoxybenzamine; D011224:Prazosin